These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

557 related items for PubMed ID: 24139092

  • 1. Guanfacine extended release: a novel treatment for attention-deficit/hyperactivity disorder in children and adolescents.
    Faraone SV, McBurnett K, Sallee FR, Steeber J, López FA.
    Clin Ther; 2013 Nov; 35(11):1778-93. PubMed ID: 24139092
    [Abstract] [Full Text] [Related]

  • 2. Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Childress AC.
    Adv Ther; 2012 May; 29(5):385-400. PubMed ID: 22610723
    [Abstract] [Full Text] [Related]

  • 3. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder.
    Wilens TE, Bukstein O, Brams M, Cutler AJ, Childress A, Rugino T, Lyne A, Grannis K, Youcha S.
    J Am Acad Child Adolesc Psychiatry; 2012 Jan; 51(1):74-85.e2. PubMed ID: 22176941
    [Abstract] [Full Text] [Related]

  • 4. Randomized, double-blind trial of guanfacine extended release in children with attention-deficit/hyperactivity disorder: morning or evening administration.
    Newcorn JH, Stein MA, Childress AC, Youcha S, White C, Enright G, Rubin J.
    J Am Acad Child Adolesc Psychiatry; 2013 Sep; 52(9):921-30. PubMed ID: 23972694
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. A phase I, randomized, open-label, crossover study of the single-dose pharmacokinetic properties of guanfacine extended-release 1-, 2-, and 4-mg tablets in healthy adults.
    Swearingen D, Pennick M, Shojaei A, Lyne A, Fiske K.
    Clin Ther; 2007 Apr; 29(4):617-25. PubMed ID: 17617285
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
    Hervas A, Huss M, Johnson M, McNicholas F, van Stralen J, Sreckovic S, Lyne A, Bloomfield R, Sikirica V, Robertson B.
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1861-72. PubMed ID: 25453486
    [Abstract] [Full Text] [Related]

  • 9. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial.
    Sallee FR, McGough J, Wigal T, Donahue J, Lyne A, Biederman J, SPD503 STUDY GROUP.
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):155-65. PubMed ID: 19106767
    [Abstract] [Full Text] [Related]

  • 10. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder.
    Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR.
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):501-10. PubMed ID: 19877974
    [Abstract] [Full Text] [Related]

  • 11. Effects of extended-release guanfacine on ADHD symptoms and sedation-related adverse events in children with ADHD.
    Faraone SV, Glatt SJ.
    J Atten Disord; 2010 Mar; 13(5):532-8. PubMed ID: 19395648
    [Abstract] [Full Text] [Related]

  • 12. Guanfacine ER for the treatment of adolescent attention-deficit/hyperactivity disorder.
    Bukstein OG, Head J.
    Expert Opin Pharmacother; 2012 Oct; 13(15):2207-13. PubMed ID: 22957772
    [Abstract] [Full Text] [Related]

  • 13. A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Wilens TE, Robertson B, Sikirica V, Harper L, Young JL, Bloomfield R, Lyne A, Rynkowski G, Cutler AJ.
    J Am Acad Child Adolesc Psychiatry; 2015 Nov; 54(11):916-25.e2. PubMed ID: 26506582
    [Abstract] [Full Text] [Related]

  • 14. Psychomotor functioning and alertness with guanfacine extended release in subjects with attention-deficit/hyperactivity disorder.
    Kollins SH, López FA, Vince BD, Turnbow JM, Farrand K, Lyne A, Wigal SB, Roth T.
    J Child Adolesc Psychopharmacol; 2011 Apr; 21(2):111-20. PubMed ID: 21476931
    [Abstract] [Full Text] [Related]

  • 15. Guanfacine extended release adjunctive to a psychostimulant in the treatment of comorbid oppositional symptoms in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, McBurnett K, White C, Youcha S.
    J Child Adolesc Psychopharmacol; 2014 Jun; 24(5):245-52. PubMed ID: 24945085
    [Abstract] [Full Text] [Related]

  • 16. The role of alpha2-adrenergic agonists in attention-deficit/hyperactivity disorder.
    Sallee FR.
    Postgrad Med; 2010 Sep; 122(5):78-87. PubMed ID: 20861591
    [Abstract] [Full Text] [Related]

  • 17. Is adjunctive pharmacotherapy in attention-deficit/hyperactivity disorder cost-effective in Canada: a cost-effectiveness assessment of guanfacine extended-release as an adjunctive therapy to a long-acting stimulant for the treatment of ADHD.
    Lachaine J, Sikirica V, Mathurin K.
    BMC Psychiatry; 2016 Jan 16; 16():11. PubMed ID: 26774811
    [Abstract] [Full Text] [Related]

  • 18. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
    Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.
    Pharmacoeconomics; 2012 Aug 01; 30(8):e1-15. PubMed ID: 22788263
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of a guanfacine extended-release formulation in children and adolescents with attention-deficit-hyperactivity disorder.
    Boellner SW, Pennick M, Fiske K, Lyne A, Shojaei A.
    Pharmacotherapy; 2007 Sep 01; 27(9):1253-62. PubMed ID: 17723079
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.